CTLA4 and head and neck squamous cell carcinoma: A randomised phase III study (NCT02369874) in patients with recurrent or metastatic HNSCC reported an objective response rate of 17.9% with durvalumab (anti-PD-L1) and 18.2% with durvalumab plus tremelimumab (anti-CTLA-4) [98].